XML 58 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue Recognition - Additional Information (Detail)
¥ in Billions
1 Months Ended 3 Months Ended
Apr. 30, 2013
USD ($)
PerformanceObligation
Apr. 30, 2012
USD ($)
Mar. 31, 2018
USD ($)
PerformanceObligation
Milestone
Mar. 31, 2017
Milestone
Dec. 31, 2017
USD ($)
Apr. 30, 2013
JPY (¥)
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Receivables     $ 0   $ 0  
Contract assets     0   0  
Contract liabilities     0   $ 0  
Remaining performance obligations     $ 0      
Number of milestone event probable of occurrence or achieved | Milestone     0 0    
Royalty revenue     $ 0      
Maruishi Agreement [Member]            
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Number of performance obligations for revenue recognized | PerformanceObligation 2   2      
Upfront non-refundable, non-creditable license fee $ 15,337,000          
Premium from sale of stock 337,000          
Maruishi Agreement [Member] | License [Member]            
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Upfront non-refundable, non-creditable license fee 9,637,000          
Estimated selling price 10,200,000          
Maruishi Agreement [Member] | R&D Services [Member]            
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Upfront non-refundable, non-creditable license fee 5,700,000          
Estimated selling price 6,200,000          
Maruishi Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]            
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Remaining potential consideration $ 10,500,000          
Maruishi Agreement [Member] | One-time Sales Milestone [Member]            
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Remaining potential consideration | ¥           ¥ 1
CKDP Agreement [Member]            
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Upfront non-refundable, non-creditable license fee   $ 646,000        
Premium from sale of stock   83,000        
CKDP Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]            
Revenue Recognition Multiple Deliverable Arrangements [Line Items]            
Remaining potential consideration   $ 3,750,000